As a tumor suppressor, SPOP mutations occur around 15% in prostate cancer, and display a mutual exclusion with PTEN deletion/mutations (Fig. S1M), indicating the potential connection of SPOP status and the PI3K-AKT signaling pathway. This evidence concerns the gene SPOP and prostate carcinoma.